Search | Clinical Trials Finder

Conditions: Healthy Volunteer, Cystic Fibrosis
Interventions: PTI-801, Placebo, PTI-808; Drug
Lead sponsor: Proteostasis Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 33
States / cities: Birmingham, Alabama • Anchorage, Alaska • Stanford, California + 28 more

Conditions: Psilocybin
Interventions: Psilocybin, Midazolam, Saline; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Dental Caries in Children, Pediatric Dental Sedation, Meperidine, Hydroxyzine, Midazolam
Interventions: Meperidine, Hydroxyzine, Midazolam; Drug
Lead sponsor: University of Washington; Other
Eligibility: 3 Years to 7 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy Volunteers
Interventions: Tasimelteon, Rosiglitazone, Midazolam; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Healthy Volunteers
Interventions: TAK-915 suspension, Midazolam, Placebo, TAK-915 tablet; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Drug Interactions
Interventions: CYP450 Cocktail and Transporter Substrates with Pacritinib, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Liver Fibrosis, Alpha-1 Antitrypsin Deficiency, AAT Deficiency, AATD
Interventions: Abdominal ultrasound, History and physical, Intravenous catheter, Blood draw, Liver questionnaire, Liver Biopsy, Midazolam, Fentanyl, Lidocaine, Acetaminophen, Lorazepam, Oxycodone/Acetaminophen, Ondansetron; Device · Procedure · Other + 1 more
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Cataract
Interventions: dexmedetomidine, Propofol, Dexemedetomidine; Drug
Lead sponsor: The Cooper Health System; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Opioid Use, Heart; Surgery, Heart, Functional Disturbance as Result, Anesthesia
Interventions: Opioid Anesthetics, Non Opioid Analgesics; Drug
Lead sponsor: Benaroya Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK1265744 30 mg oral, Midazolam 3 mg oral + GSK1265744 30mg oral, GSK1265744 400 mg (200 nm), GSK1265744 400 mg (1 micro m), GSK1265744 400 mg (5 micro m); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: PF-07817883, Placebo, Midazolam, Moxifloxacin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Solid Tumours
Interventions: CYP1A2 (caffeine), CYP2C19 (omeprazole), CYP3A (midazolam), Kytril (granisetron), Wee-1 kinase inhibitor AZD1775; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more

Conditions: Sedation, Conscious
Interventions: Midazolam, xylocaine, saline placebo; Drug
Lead sponsor: Bassett Healthcare; Other
Eligibility: 18 Months to 7 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Cooperstown, New York

Conditions: Healthy Volunteers, Pharmacologic Action
Interventions: Group 1 AZD3293, Group 2 AZD3293, Group 3 AZD3293, Group 1 Itraconazole, Group 2 Diltiazem, Group 3 Midazolam; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cypress, California

Conditions: Posttraumatic Stress Disorder (PTSD)
Interventions: Ketamine, Midazolam; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Total Hip Arthroplasty
Interventions: PENG Block, Lidocaine; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Birmingham, Alabama

Conditions: Sepsis
Interventions: Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure, Midazolam, Volitional Measurement of Maximal Inspiratory Pressure (MIP), Inspiratory Muscle Strength Training (IMST), SHAM Inspiratory Muscle Strength Training (IMST), Diaphragm thickness measurement, Blood and Urine samples; Procedure · Drug · Device + 1 more
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Laparoscopic Gastric Bypass Surgery, Ketamine
Interventions: Ketamine, Standard therapy; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 69 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Endoscopic Ultrasound (EUS), Endoscopic Retrograde Cholangiopancreatography (ERCP)
Interventions: Meperidine, Midazolam, Diphenhydramine, Promethazine; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 304 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Orange, California

Conditions: Respiratory Failure
Interventions: Midazolam, Normal saline, Fentanyl; Drug
Lead sponsor: Javier Gelvez, MD; Other
Eligibility: Up to 18 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Cataract Surgery, Cognitive Impairment
Interventions: Remimazolam, Midazolam; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 65 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections
Interventions: Part A, C and D: VH3739937 500 mg, Part A: VH3739937 100 mg, Part A and C: Placebo, Part B: Treatment A, Part B: Treatment B, Part B: Treatment C, Part B: Treatment D, Part B: Treatment E, Part D: Probe cocktail; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cataract
Interventions: Diazepam, Tramadol, Ondansetron, MKO melt; Drug
Lead sponsor: Avanti Anesthesia; Other
Eligibility: 18 Years and older
Enrollment: 651 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Carotid Artery Stenosis
Interventions: Remifentanil, Propofol, and Desflurane, Remifentanil, Dexmedetomidine, and Desflurane, Remifentanil and Desflurane; Drug
Lead sponsor: The Cooper Health System; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Camden, New Jersey

Search by objective public record fields.

Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

The RECAP2 Study: Midazolam and Psilocybin

Comparing Pediatric Dental Oral Sedation Outcomes With and Without Meperidine in Children Aged 3-7 Years

A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects

Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study

Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)

Dexmedetomidine vs. Propofol for Cataract Surgery

Opioid-free Anesthesia for Open Cardiac Surgery: A Prospective Randomized Controlled Trial

A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects

A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People

Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

Intranasal Midazolam in Children as a Pre-Operative Sedative

A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate

Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD)

Trial Comparing Impact of PENG Block on Quality of Recovery Compared to No-block for Primary Total Hip Arthroplasty

Project 4A: Inspiratory Muscle Training and Diaphragm Strength

Perioperative Ketamine for Pain With Gastric Bypass

Adjunct Sedatives in Endoscopic Ultrasound (EUS) and Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures

Cycling of Sedative Infusions in Critically Ill Pediatric Patients

Remimazolam for Cataract Surgery

VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)

Conscious Sedation Efficacy of the MKO Melt (Midazolam, Ketamine, Ondansetron)

Time to Post-Anesthesia Neurological Evaluation With Three Different Anesthetic Techniques